biostudies-literatureMa YTEfficacy and Mechanism Evaluation ProgrammeEfficacy and Mechanism Evaluation Programme (EME)3412-3423https://www.ebi.ac.uk/biostudies/studies/S-EPMC12351282biostudies-literatureUnknown31(16)<h4>Purpose</h4>A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma.<h4>Patients and methods</h4>A randomized phase II trial was conducted in three tertiary referral centers in the United Kingdom. Eligible patients were randomly assigned in a 1:1 ratio to TACE + preconditioning cyclophosphamide or to TACE + preconditioning cyclophosphamide + DC infusions. The primary endpoint was progression-free survival time using RECIST v1.1 criteriClinical cancer research : an official journal of the American Association for Cancer ResearchAddition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial.PMC1235128209/160/24Mehrzad HRowe ALWebster LBathurst CPunia PMa YTSylla PRao AJames MWHull DKirkham AStern NLowe FZuo JHussain SPalmer DAdams DHYap CKarkhanis SCurbishley SBlahova MfalseAddition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial.<h4>Purpose</h4>A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma.<h4>Patients and methods</h4>A randomized phase II trial was conducted in three tertiary referral centers in the United Kingdom. Eligible patients were randomly assigned in a 1:1 ratio to TACE + preconditioning cyclophosphamide or to TACE + preconditioning cyclophosphamide + DC infusions. The primary endpoint was progression-free survival time using RECIST v1.1 criteri2025-01-01T00:00:00Z2025 Aug2026-05-29T14:26:05.888Z2026-04-08T05:03:05.274ZS-EPMC123512824049914410.1158/1078-0432.CCR-25-0142